About Transition Therapeutics (NASDAQ:TTHI)
Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-58.00%
Return on Assets-47.29%
Miscellaneous
EmployeesN/A
Outstanding Shares38,880,000
Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions
What is Transition Therapeutics' stock symbol?
Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."
How were Transition Therapeutics' earnings last quarter?
Transition Therapeutics Inc (NASDAQ:TTHI) released its quarterly earnings data on Tuesday, September, 15th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.
Has Transition Therapeutics been receiving favorable news coverage?
Media headlines about TTHI stock have been trending positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transition Therapeutics earned a coverage optimism score of 0.42 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 43.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Transition Therapeutics?
Shares of TTHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transition Therapeutics' stock price today?
One share of TTHI stock can currently be purchased for approximately $1.52.
How can I contact Transition Therapeutics?
Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.
MarketBeat Community Rating for Transition Therapeutics (TTHI)
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Transition Therapeutics (NASDAQ:TTHI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | N/A |
| Consensus Rating Score: | N/A | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Transition Therapeutics (NASDAQ:TTHI) Consensus Price Target History
Transition Therapeutics (NASDAQ:TTHI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/14/2016 | Cowen | Reiterated Rating | Hold | | N/A |  |
(Data available from 4/25/2016 forward)
Transition Therapeutics (NASDAQ:TTHI) Earnings History and Estimates Chart
Transition Therapeutics (NASDAQ TTHI) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2016 | Q3 2016 | | ($0.08) | | | View | N/A | |
| 2/9/2016 | Q2 2016 | | ($0.04) | | | View | N/A | |
| 11/10/2015 | Q1 2016 | | ($0.09) | | | View | N/A | |
| 9/15/2015 | Q415 | ($0.39) | ($0.31) | | | View | N/A | |
| 5/12/2015 | Q315 | ($0.20) | ($0.11) | | | View | N/A | |
| 2/10/2015 | | ($0.24) | ($0.38) | | | View | N/A | |
| 11/12/2014 | Q312 | ($0.18) | ($0.45) | | | View | N/A | |
| 9/26/2014 | | ($0.28) | ($0.39) | | | View | N/A | |
| 5/14/2014 | | ($0.07) | ($0.16) | | | View | N/A | |
| 2/12/2014 | Q2 2014 | ($0.11) | ($0.04) | | | View | N/A | |
| 11/12/2013 | | ($0.11) | ($0.08) | | | View | N/A | |
| 9/11/2013 | Q4 2013 | $0.15 | $0.17 | $7.00 million | $6.90 million | View | N/A | |
| 5/7/2013 | Q3 2013 | | ($0.11) | | | View | N/A | |
| 2/7/2013 | Q2 2013 | ($0.11) | ($0.10) | | | View | N/A | |
| 11/8/2012 | Q1 2013 | | $0.29 | | | View | N/A | |
| 9/13/2012 | Q4 2012 | | ($0.10) | | | View | N/A | |
| 5/8/2012 | Q3 2012 | ($0.19) | ($0.11) | | | View | N/A | |
| 2/9/2012 | Q2 2012 | ($0.17) | ($0.15) | | | View | N/A | |
| 12/1/2011 | Q1 2012 | ($0.15) | ($0.12) | | | View | N/A | |
| 9/19/2011 | Q4 2011 | ($0.22) | ($0.17) | | | View | N/A | |
| 5/10/2011 | Q3 2011 | ($0.01) | ($0.14) | | | View | N/A | |
| 2/7/2011 | Q2 2011 | $0.23 | $1.05 | | | View | N/A | |
| 11/11/2010 | Q1 2011 | ($0.21) | ($0.19) | | | View | N/A | |
| 9/27/2010 | Q4 2010 | ($0.21) | ($0.20) | | | View | N/A | |
| 5/10/2010 | Q3 2010 | ($0.17) | ($0.13) | | | View | N/A | |
| 2/10/2010 | Q2 2010 | | ($0.20) | | | View | N/A | |
| 11/10/2009 | Q1 2010 | ($0.28) | ($0.23) | | | View | N/A | |
| 5/13/2009 | Q3 2009 | ($0.28) | ($0.31) | | | View | N/A | |
| 2/11/2009 | Q2 2009 | ($0.24) | ($0.17) | | | View | N/A | |
| 11/10/2008 | Q1 2009 | ($0.21) | ($0.21) | | | View | N/A | |
| 5/14/2008 | Q3 2008 | ($0.17) | ($0.22) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Transition Therapeutics (NASDAQ:TTHI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Transition Therapeutics (NASDAQ TTHI) Insider Trading and Institutional Ownership History
Transition Therapeutics (NASDAQ TTHI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Transition Therapeutics (NASDAQ TTHI) News Headlines
| Source: |
|
Transition Therapeutics (NASDAQ:TTHI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Transition Therapeutics (NASDAQ:TTHI) Income Statement, Balance Sheet and Cash Flow Statement
Transition Therapeutics (NASDAQ TTHI) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
